Prasenjit Bhowmik, Chief Executive Officer at SRK Analytics and Consulting Private Limited, shared a post on LinkedIn:
“Novel Blood-Based Diagnostic Tool Offers Early Warning for Lung Cancer
Researchers have identified a new blood-based risk score capable of predicting lung cancer development up to five years before a formal clinical diagnosis, according to findings published this Thursday.
The study, which marks a significant shift toward proactive oncology, utilizes a specialized biomarker analysis to identify high-risk individuals long before traditional symptoms or imaging abnormalities emerge. By pinpointing these biological indicators, the medical community aims to transition from late-stage treatment to early intervention for the world’s deadliest cancer….”
Patrick C. Ma, Associate Director of Translational Research, Penn State Cancer Institute, shared this post, adding:
“The Lung Cancer Diagnostics paradigm is clearly shifting fast these days. Exciting time and I’m eagerly awaiting for more studies and data-driven validation of new early detection and early prevention tools and pathways to further improve the lung cancer incidence and outcomes.”
